Expert: Joana Ribeiro, Champalimaud Clinical Center, Lisbon, Portugal
1-Define breast cancer with NE differentiation and distinguish it from NEC
2-Discuss neuroendocrine differentiation as an independent adverse prognostic factor for shorter OS / DFS
3-Discuss Ki 67and differentiation between NET / NEC and OS / DFS
4-Discuss adjuvant treatment- according to the same recommendations given for the other types of invasive breast cancer?
5-In the metastatic setting: types of chemotherapy in NEC and multimodality approach including specific therapies such as peptide receptor radionuclide therapy
